Enrollment Completed in SafePass 2 Study of Emboline’s Embolic Protection Catheter for TAVR

 

January 15, 2020—Emboline, Inc. announced the completion of enrollment in the company’s SafePass 2 clinical study of the Emboliner embolic protection catheter for use with transcatheter aortic valve replacement (TAVR). Final data analysis is now underway for the full SafePass 2 study population.

The data will be used to file for European CE Mark approval for the Emboliner in 2020. Additionally, the company will be seeking FDA approval to begin the pivotal United States clinical study.

According to the company, the prospective, nonrandomized, multicenter, open-label SafePass 2 study is being conducted at three centers in New Zealand to assess the safety and technical performance of the second-generation Emboliner device.

Mark Webster, MD, of Auckland City Hospital, in Auckland, New Zealand, is the principal investigator for the SafePass 2 study. Dr. Webster commented in the company’s announcement, “We were enthusiastic about participating in the SafePass 2 study, as the concept of full cerebral, renal, and peripheral vascular protection is appealing. We found the learning curve for Emboliner to be relatively short, the device easy to use, and we were impressed by the captured debris.”

The 30-day results from the first 24 patients treated using the Emboliner device were presented at TCT 2019, the 31st annual Transcatheter Cardiovascular Therapeutics scientific symposium, held September 25–29 in San Francisco, California. The findings included:

  • No device-related adverse events
  • No device-related access site complications
  • 100% technical performance (successful access of the aortic arch with the delivery catheter, positioning across the aortic arch, retrieval and removal of the device)
  • Debris capture and removal in 100% of patients

The study also examined the amount of debris collected from patients. An average of 250 particles of debris ≥ 150 µm in size were removed from each patient, with more than half of patients having debris ≥ 1 mm in size, and one in four patients having debris ≥ 2 mm in size.

The company stated that the Emboliner device is designed to provide total embolic protection of the brain and body during TAVR. The cylindrical nitinol mesh device covers the entire arterial bed (all three cerebral branches and noncerebral vessels) and contains an expandable access port through which TAVR devices are passed, enabling the device to capture and contain debris during the entire TAVR procedure. It requires no additional procedural access and minimal added procedural time.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.